NCT02848131View on ClinicalTrials.gov

Senescence in Chronic Kidney Disease

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Chronic Kidney Disease
Interventions
DRUG

Group 2: Dasatinib

Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.

DRUG

Group 2: Quercetin

Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.

Trial Locations (2)

32224

Mayo Clinic Florida, Jacksonville

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER